If your only goal is to raise and hold serum 25-hydroxyvitamin D, cholecalciferol (vitamin D3) is the more reliable choice for most adults. That is the direction a systematic review and meta-analysis of daily supplementation points in: at a given dose, D3 raises total 25(OH)D more than ergocalciferol (vitamin D2). The exception worth knowing is that this is a comparison about a blood level, not about whether you feel or function differently – and that distinction decides how much weight to give it.
What are the two forms, and are they even the same compound?
They are not the same compound. Cholecalciferol (D3) is the form your skin makes from a cholesterol precursor under UVB light, and the form found in oily fish and animal foods. Ergocalciferol (D2) is produced by irradiating ergosterol from yeast and fungi, and is the form behind many UV-treated mushroom and plant-based products. The two differ by a methyl group and a double bond in the side chain.
Not to be confused with: calcidiol (the 25(OH)D your blood test measures) and calcitriol (the active hormone). D2 and D3 are the raw dietary forms your body has to convert; they are not the thing the assay reads or the thing that acts on your tissues.
Because they are different molecules, you cannot assume evidence transfers automatically from one to the other. Each has to earn its result. That is precisely why a head-to-head comparison of the two, rather than two separate placebo comparisons, is the only thing that can settle which raises the biomarker more.
What criteria actually matter here?
For this decision, in order of weight:
- Does it raise and sustain serum 25(OH)D per unit dose? This is the measured endpoint and the one the comparison can actually answer.
- Is it stable and cheap at the dose you need? A form you will keep taking beats a marginally better one you will not.
- Does it fit a dietary restriction? D2 is the plant/fungal-sourced option; that matters for some readers regardless of biomarker performance.
A criterion many arrive with that does not decide this comparison: which form produces better health outcomes – fewer fractures, fewer infections, lower mortality. That question is about clinical endpoints, and neither form's edge on a blood level answers it. Keep the two apart.
What does the direct comparison show?
A 2024 systematic review and meta-analysis in Advances in Nutrition pooled trials of daily D2 versus daily D3 supplementation and looked at their effect on serum 25(OH)D. Across that evidence, D3 raised total 25(OH)D more effectively than D2 at comparable daily dosing. The review also examined the separate fractions the assay can distinguish – 25(OH)D2 and 25(OH)D3 – and flagged body mass index as a factor that shapes the response.
Two things are worth reading carefully. First, this is a comparison of a surrogate biomarker. A higher 25(OH)D reading demonstrates that D3 does its immediate job – putting more measurable vitamin D into circulation – more efficiently than D2. It does not, on its own, demonstrate a clinical benefit; that sits one tier further along the evidence chain. Second, because the analysis pooled daily supplementation, it speaks most directly to daily dosing. Large intermittent boluses can behave differently, and that is a separate question this comparison does not resolve.
Where is the comparison weak or overstated?
The biomarker gap is the established part. What marketing tends to do is let it drift into a health claim – implying that because D3 raises the number more, it must protect bones or immunity more. That step is not supported by a comparison of blood levels. If you care about a clinical endpoint, the closest thing to an answer is indirect. A 2019 meta-analysis of 52 randomised trials in 75,454 adults found no association between vitamin D supplementation and all-cause mortality overall; in a subgroup comparison, all-cause mortality was lower in the trials that used D3 than in the trials that used D2 (P for interaction 0.04), while neither form on its own reached a significant reduction. That is a comparison between separate trials, not a head-to-head test of the two forms, and it needs a dedicated study before it can mean anything at the shelf.
Body mass index complicates the individual picture. Because vitamin D distributes into fat tissue, the same dose produces a smaller rise in serum 25(OH)D in people with higher BMI, for either form. The measured superiority of D3 is an average across pooled trials; your own response depends on your starting level, your body composition, and your dose. The direction of the finding is robust; the size of the gap for any one person is not something a pooled average can hand you.
How does the difference arise, mechanistically?
Both forms are hydroxylated in the liver to 25(OH)D and then in the kidney to the active hormone. The leading mechanistic explanation for D3's edge is that 25(OH)D3 appears to be cleared more slowly and binds vitamin D-binding protein somewhat differently than 25(OH)D2, so a given intake of D3 tends to hold a higher circulating level over time. Treat that as a plausible mechanism consistent with the measured result – it explains the biomarker finding; it does not add a separate layer of proof about outcomes.
One practical detail sits upstream of that and applies to both forms. A systematic review of intestinal vitamin D absorption concluded that uptake is not simple passive diffusion alone but also involves membrane carriers, especially cholesterol transporters, and that some data suggest a fat-containing meal improves absorption – while noting that the underlying data are scarce. Absorption still happens without fat, so this is a way to get a little more out of the dose you already take, not a reason to change form.
Who should choose which?
- Most adults correcting or maintaining vitamin D status: D3 is the sensible default. It raises the biomarker more per unit dose, it is widely available, and it is inexpensive. That is a decision resting on biomarker-supported evidence, not on demonstrated clinical superiority.
- Vegans and others avoiding animal-derived ingredients: D2, or a lichen-derived D3 where acceptable, is the workable option. D2 still raises 25(OH)D; it simply does so less efficiently, which you can offset with dose and monitoring rather than switching principle.
- People with higher BMI: the form matters less than the recognition that any given dose moves the number less. This is a dosing-and-retesting question more than a D2-versus-D3 one.
Verdict
On the question actually asked – which form raises serum 25(OH)D more in adults – the comparison is settled with a clear direction: cholecalciferol, at comparable daily doses. On the larger question people quietly attach to it – which form is better for your health – the comparison does not reach that far, and no amount of biomarker advantage substitutes for outcome data that this evidence does not provide.
The rule to carry to the next product you pick up: a form that raises a lab value more efficiently has proven exactly that and nothing beyond it. Whether to buy on the biomarker depends on whether the biomarker is what you actually care about – and for maintaining vitamin D status, it reasonably is.
Sources
- Comparison of the Effect of Daily Vitamin D2 and Vitamin D3 Supplementation on Serum 25-Hydroxyvitamin D Concentration (Total 25(OH)D, 25(OH)D2, and 25(OH)D3) and Importance of Body Mass Index: A Systematic Review and Meta-Analysis (Adv Nutr, 2024) – basis for the finding that daily D3 raises total serum 25(OH)D more than daily D2, and that BMI shapes the response.
- Association between vitamin D supplementation and mortality: systematic review and meta-analysis (BMJ, 2019) – 52 randomised trials, 75,454 adults; basis for the statement that supplementation was not associated with all-cause mortality and that the D3-versus-D2 difference on that endpoint is a between-trial subgroup comparison only.
- Intestinal absorption of vitamin D: a systematic review (Nutr Rev) – basis for the absorption mechanism and for the note that a fat-containing meal appears to improve uptake.
